Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

Mon, 26 Oct 2026 08:32:00 -0400

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice President of Product Development of Daré Bioscience, will present on the Company’s Intelligent Drug Delivery System (DARE-IDDS)

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

Mon, 26 Oct 2026 08:32:00 -0400

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston

Ladenburg Thalmann Starts Dare Bioscience (DARE) at Buy

Mon, 26 Oct 2026 06:56:11 -0400

Ladenburg Thalmann analyst Jeff initiates coverage on Dare Bioscience (NASDAQ: DARE) with a Buy rating and a price target of $2.00.

For an analyst ratings summary and ratings history on Dare Bioscience click here. For more ratings news on Dare Bioscience click here.

Shares of Dare Bioscience closed at $0.65 yesterday.

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Mon, 19 Oct 2026 08:56:00 -0400

Premier sponsorship of the HERmedicine and OncoMenopause Consortium^® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer

The program addresses non-hormonal approaches to women’s sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6%

Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society's 2026 Annual Meeting

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Mon, 19 Oct 2026 08:56:00 -0400

The program addresses non-hormonal approaches to women’s sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6%

Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society's 2026 Annual Meeting

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

Tue, 13 Oct 2026 09:15:00 -0400

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities

Access the CEO Corner here

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its CEO Corner, a new video series featuring Founder, President and CEO Sabrina Martucci Johnson.

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

Tue, 13 Oct 2026 09:15:00 -0400

Access the CEO Corner here

Daré Bioscience to present sildenafil cream Phase 1 data at SMSNA

Thu, 08 Oct 2026 09:15:19 -0400

Daré Bioscience, Inc. (NASDAQ: DARE) announced it will present Phase 1 clinical data for its proprietary Sildenafil Cream, 3.6% at the Sexual Medicine Society of North America Annual Fall Scientific Meeting, taking place October 8-11, 2026, in Orlando, Florida.

Annie Thurman, MD, FACOG, Medical Director of Daré Bioscience, will present findings from the open-label, single-dose, randomized study during the Innovations in Sexual Medicine Abstracts session on October 9, 2026. The study compared the safety and relative bioavailability of topical Sildenafil Cream with oral sildenafil in healthy adult men.

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Thu, 08 Oct 2026 09:15:00 -0400

Medical Director Annie Thurman, MD, FACOG to present adverse event and relative bioavailability data comparing topical Sildenafil Cream with oral sildenafil in healthy male adults

SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that clinical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA),

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Thu, 08 Oct 2026 09:15:00 -0400

Medical Director Annie Thurman, MD, FACOG to present adverse event and relative bioavailability data comparing topical Sildenafil Cream with oral sildenafil in healthy male adults

Form DEF 14A Dare Bioscience, Inc. For: Oct 06

Tue, 06 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27156240.html

Form 8-K Dare Bioscience, Inc. For: Sep 28

Fri, 02 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27141991.html

Form 8-K Dare Bioscience, Inc. For: Oct 01

Thu, 01 Oct 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20261001/27132698.html

Dare Bioscience stock rises after receiving HPV treatment patent

Mon, 28 Sep 2026 10:12:59 -0400

Investing.com -- Dare Bioscience Inc (NASDAQ:DARE) shares rose 2.8% on Monday following the announcement that the company received a new U.S. patent for its HPV treatment program.

The patent, titled "Lopinavir and Ritonavir for the Treatment of Cervix Disorders," was issued by the United States Patent and Trademark Office on July 14, 2026, to Douglas Pharmaceuticals Limited, a licensor to Dare Bioscience. The patent covers pharmaceutical compositions formulated for topical application comprising lopinavir and ritonavir for the treatment of HPV-related cervical pathologies and is expected to provide protection into at least 2039.

The patent

Dare Bioscience stock rises after receiving HPV treatment patent

Mon, 28 Sep 2026 10:12:59 -0400

Investing.com -- Dare Bioscience Inc (NASDAQ:DARE) shares rose 2.8% on Monday following the announcement that the company received a new U.S. patent for its HPV treatment program.

The patent

Daré Bioscience receives new U.S. patent for HPV treatment program

Mon, 28 Sep 2026 08:25:27 -0400

Daré Bioscience (NASDAQ: DARE) announced the issuance of U.S. Patent No. 12,678,439, covering pharmaceutical compositions of lopinavir and ritonavir formulated for topical application in the treatment of HPV-related cervical pathologies, according to a company press release.

The patent was issued by the United States Patent and Trademark Office on July 14, 2026, to Douglas Pharmaceuticals Limited, which licenses the technology to Daré Bioscience. The patent includes claims for compositions designed to treat or inhibit early-stage neoplasias and to treat or prevent HPV-related cervical neoplasias. Protection is expected to extend into at least 2039. Daré holds an exclusive U.S. license to the

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

Mon, 28 Sep 2026 08:20:00 -0400

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award

DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

Mon, 28 Sep 2026 08:20:00 -0400

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven

Form PRE 14A Dare Bioscience, Inc. For: Sep 23

Wed, 23 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260923/27096752.html

Daré Bioscience publishes Phase 1 sildenafil cream data in men

Mon, 14 Sep 2026 08:50:19 -0400

Daré Bioscience (NASDAQ: DARE) announced the publication of results from a Phase 1 clinical study evaluating the safety and systemic pharmacokinetics of its topical Sildenafil Cream, 3.6% in healthy adult men. The findings were published in Sexual Medicine, an official journal of the International Society for Sexual Medicine.

The open-label, randomized study enrolled 62 healthy men who received a single dose of either 36 mg or 71 mg of sildenafil in topical cream form, with or without condom use, or a 50 mg oral dose of sildenafil in tablet form. The study evaluated safety and systemic pharmacokinetics of sildenafil and its

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Mon, 14 Sep 2026 08:50:00 -0400

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6%

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose

Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation

SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Mon, 14 Sep 2026 08:50:00 -0400

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6%

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose

Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation

Form 8-K Dare Bioscience, Inc. For: Sep 10

Fri, 11 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260911/27053215.html

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Fri, 11 Sep 2026 06:55:00 -0400

View the video webcast here

SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, provides an overview of the Company as well as recent corporate

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Fri, 11 Sep 2026 06:55:00 -0400

View the video webcast here

The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, provides an overview of the Company as well as recent corporate

StreetInsider.com News Articles

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

Ladenburg Thalmann Starts Dare Bioscience (DARE) at Buy

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

Daré Bioscience to present sildenafil cream Phase 1 data at SMSNA

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Form DEF 14A Dare Bioscience, Inc. For: Oct 06

Form 8-K Dare Bioscience, Inc. For: Sep 28

Form 8-K Dare Bioscience, Inc. For: Oct 01

Dare Bioscience stock rises after receiving HPV treatment patent

Dare Bioscience stock rises after receiving HPV treatment patent

Daré Bioscience receives new U.S. patent for HPV treatment program

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

Form PRE 14A Dare Bioscience, Inc. For: Sep 23

Daré Bioscience publishes Phase 1 sildenafil cream data in men

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Form 8-K Dare Bioscience, Inc. For: Sep 10

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand